期刊文献+

放射治疗对肺癌患者NKG2D、HMGB1及DC细胞活性的影响 被引量:2

Effect of radiation therapy on NKG2D, HMGB1 and DCs cell of lung cancer patients
下载PDF
导出
摘要 目的分析接受放射治疗(以下简称放疗)肺癌患者在放疗不同阶段外周血细胞因子NKG2D、高迁移率蛋白1(HMGB1)的变化及与树突状细胞(DC细胞)活性的相关性。方法选取承德医学院附属医院30例肺癌放疗患者,分别在放疗前及放疗后不同时段通过ELISA检测NKG2D、HMGB1,通过免疫磁珠法检测DC细胞。结果 HMGB1、NKG2D的浓度于放疗2 000、4 000及6 000 cGy时逐渐下降(P<0.05)。DC细胞活性差异无统计学意义(P<0.05)。DC细胞与HMGB1、NKG2D无相关性(r=-0.204和0.105,P=0.281和0.580)。结论放射治疗可降低肺癌患者HMGB1、NKG2D的水平,激活免疫功能,但对肺癌患者外周血中DC细胞的活性无影响,外周血中DC细胞活性与HMGB1、NKG2D无相关。 Objective To analyze the dynamic changes of NKG2 D, HMGB1 in peripherd blood of patients with lung cancer before and after different dose radiotherapy, and to analyze the relationship between DCs and NKG2 D, HMGB1. Method A total of 30 patients with lung cancer were included in the study. The NKG2 D and HMGB1 were detected by ELISA method, and the DCs were detected by MACS(magnetic activated cell sorting) before and after radiotherapy. Results HMGB1 and NKG2 D gradually decreased after 2 000 c Gy, 4 000 c Gy and 6 000 c Gy radiotherapy(P<0.05). The activity changes of DCs in the serum of the patients with lung cancer before and after radiotherapy have no significant difference(P>0.05). There was no correlation between DCs and HMGB1, NKG2 D(r=-0.204 and 0.105, P=0.281 and 0.580). Conclusion Radiation therapy can reduce the level of HMGB1 and NKG2 D, and activate the cellular immune function. However, radiotherapy has no effect on the activity of DCs in peripheral blood of patients with lung cancer, and there was no correlation between DCs and cytokines(HMGB1, NKG2 D) in peripheral blood.
作者 白璐 张晶晶 高东奇 刘承一 于晓磊 李文鑫 李青山 Lu Bai;Jing-jing Zhang;Dong-qi Gao;Cheng-yi Liu;Xiao-lei Yu;Wen-xin Li;Qing-shan Li(Department of Oncology,The Affiliated hospital of Chengde Mediacal Collage,Cheng,Hebei 067000,China)
出处 《中国现代医学杂志》 CAS 2020年第1期31-35,共5页 China Journal of Modern Medicine
基金 承德市科技计划支撑项目(NO:201701A036)
关键词 肺肿瘤 放射治疗 NKG2D HMGB1 DC细胞 lung neoplasms radiotherapy NKG2D HMGB1 protein dendritic cells
  • 相关文献

参考文献4

二级参考文献22

  • 1孙伟红,魏晓芳,赵鹏,李长优,高岱清.胃癌患者DC-CIK治疗前后外周血Treg细胞及相关细胞因子的变化[J].中国肿瘤生物治疗杂志,2015,22(1):79-83. 被引量:16
  • 2Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol, 2006, 6(11): 836-848. 被引量:1
  • 3Kim R, EmiM, Tanabe K. Cancer immunoediting from immune surveillance to immune escape.Immunology, 2007, 121 (1): 1-14. 被引量:1
  • 4Coudert JD, Held W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol, 2006, 16(5): 333-343. 被引量:1
  • 5Terabe M, Berzofsky JA. The role of NKT cell in tumor immunity. Adv Cancer Res, 2008, 101:277-348. 被引量:1
  • 6Baev DV, Peng XH, Song L, et al. Distinct homeostatic requirements of CD4^+ and CD4^- subsets of V α-24 invariant natural killer T cells in humans. Blood, 2004, 104(13): 4150-4156. 被引量:1
  • 7Groh V, Wu J, Yee C, et al. Tumor-devived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 2002, 419(6908): 734-738. 被引量:1
  • 8Maccalli C, Scaramuzza S, Parmiani G. TNK cells (NKG2D^+CD8^+ or CD4^+T lymphocytes) in the control of human tumors. Cancer Immunol Immunother, 2009, 58(5): 801-808. 被引量:1
  • 9Burgess SJ, Maasho K, Masilamani M, et al. The NKG2D receptor: immunobiology and clinical implications. Immunol Res, 2008, 40(1): 18-34. 被引量:1
  • 10Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res, 2004, 64(20): 7596-7603. 被引量:1

共引文献26

同被引文献23

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部